RB1 and breast carcinoma: The major mechanisms of endocrine resistance in ER+ breast cancers, through ERα itself, receptor tyrosine kinase (RTK) signaling, or cell cycle regulation with the cyclin D-CDK4/6-Rb pathway, have been demonstrated to be pivotal in endocrine therapy2.